Zydus Cadila gets USFDA nod for Pemetrexed for Injection
Ahmedabad: Drug major, Zydus Cadila, has recently announced that the company has received tentative approval from the United States Food & Drug Administration (USFDA) to market Pemetrexed for Injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials (US RLD: Alimta).
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma.
It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila gets USFDA nod for multiple sclerosis drug Fingolimod
Read also: Cadila Healthcare, Bayer to extend JV Bayer Zydus Pharma by 3 years
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd